The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation
Open accessAbstract
Severe COVID‐19 is distinct from ARDS and cytokine‐release syndromes Published data [1, 2], anecdotal observations, and discussions with colleagues worldwide indicate that COVIDinduced respiratory phenotypes are distinct from typical ARDS in several ways [2]. COVID-19 patients develop profound hypoxemia early in their disease course. However, overt respiratory dysfunction at these early stages is unusual. Pulmonary compliance in intubated COVID19 patients appears to be only modestly decreased, and patients are therefore relatively easy to ventilate [1]. Gattinoni et al. [1] described hyperperfusion of poorly ventilated lung, perhaps due to vasodilation and the loss of hypoxic vasoconstriction. While benefit from low-tomoderate levels of PEEP and prone positioning have been noted, these authors suggest that they result more from hemodynamics effects than lung recruitment [1]. Later in the course of COVID-19, some patients develop a phenotype more consistent with ARDS [1, 2]. The reported inflammatory response in COVID19 is also not consistent with either typical ARDS or cytokine-release syndromes (CRS) or “cytokine storm.” Qin et al. [3] report mean interleukin-6 levels were 25 (SD: 10–55) pg/mL (normal range: 7 pg/mL). Other smaller COVID-19 reports have ranged from 7 to 125 pg/ mL. These findings contrast with interleukin-6 elevations seen in typical ARDS and in CRS. Sinha et al. report mean interleukin-6 levels of 282 (111–600) pg/mL in “hypoinflammatory” ARDS [9] and 1618 (517–3205) pg/mL in hyperinflammatory ARDS [4], 10to 60-fold higher than reported in the Wuhan data. Among CRS patients, mean interleukin-6 levels are frequently as high as 10,000 pg/mL [5]. Other inflammatory cytokines (e.g., interleukin-8, interleukin-1β) demonstrate similar patterns. In summary, COVID-19 is associated with only mild inflammatory cytokine elevation and demonstrates physiology and immunology that are difficult to reconcile with ARDS or CRS. An alternative mechanism of disease therefore seems likely.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · cited 1×
“Other inflammatory cytokines (e.g., interleukin-8, interleukin-1β) demonstrate similar patterns.”
BackgroundDysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa248 · Cited by 4,775
Coronaviruses: An Overview of Their Replication and Pathogenesis
Fehr, A. R., & Perlman, S. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2438-7_1 · Cited by 3,787
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19
Zhang, Y., Xiao, M., Zhang, S., Xia, P., Cao, W., Jiang, W., Chen, H., Ding, X., Zhao, H., Zhang, H., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2007575 · Cited by 2,179
Liu, Y., Yang, Y., Zhang, C., Huang, F., Wang, F., Yuan, J., Wang, Z., Li, J., Li, J., Feng, C., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1643-8 · Cited by 2,031
COVID-19 pneumonia: different respiratory treatments for different phenotypes?
Gattinoni, L., Chiumello, D., Caironi, P., Busana, M., Romitti, F., Brazzi, L., & Camporota, L. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06033-2 · Cited by 1,852
Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China
Su, H., Yang, M., Wan, C., Yi, L.-X., Tang, F., Zhu, H.-Y., Yi, F., Yang, H.-C., Fogo, A. B., Nie, X., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.04.003 · Cited by 1,755
Tian, S., Hu, W., Niu, L., Liu, H., Xu, H., & Xiao, S.-Y. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.02.010 · Cited by 1,414
COVID-19 Does Not Lead to a “Typical” Acute Respiratory Distress Syndrome
Gattinoni, L., Coppola, S., Cressoni, M., Busana, M., Rossi, S., & Chiumello, D. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202003-0817le · Cited by 1,396
Liu, Z., Xiao, X., Wei, X., Li, J., Yang, J., Tan, H., Zhu, J., Zhang, Q., Wu, J., & Liu, L. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25726 · Cited by 691
Cited by
Leisman, D. E., Ronner, L., Pinotti, R., Taylor, M. D., Sinha, P., Calfee, C. S., Hirayama, A. V., Mastroiani, F., Turtle, C. J., Harhay, M. O., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30404-5 · Cited by 855
Self-citationThe vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection
Pons, S., Fodil, S., Azoulay, E., & Zafrani, L. (2020) · Critical Care · doi:10.1186/s13054-020-03062-7 · Cited by 517
Pathophysiology of COVID-19-associated acute kidney injury
Legrand, M., Bell, S., Forni, L., Joannidis, M., Koyner, J. L., Liu, K., & Cantaluppi, V. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00452-0 · Cited by 500
Self-citationThe coagulopathy, endotheliopathy, and vasculitis of COVID-19
Iba, T., Connors, J. M., & Levy, J. H. (2020) · Inflammation Research · doi:10.1007/s00011-020-01401-6 · Cited by 429
Grimaud, M., Starck, J., Levy, M., Marais, C., Chareyre, J., Khraiche, D., Leruez-Ville, M., Quartier, P., Léger, P. L., Geslain, G., et al. (2020) · Annals of Intensive Care · doi:10.1186/s13613-020-00690-8 · Cited by 319
Metadata
- Authors
- Leisman, D. E., Deutschman, C. S., & Legrand, M.
- Venue
- Intensive Care Medicine
- Published
- 2020-04-28
- Volume
- 46
- Issue
- 6
- Pages
- 1105-1108
- ISSN
- 0342-4642 (ISSN-L)
- 1432-1238
- OpenAlex
- W3018529391
- Cited by
- 332
- References
- 13
- FWCI
- 9.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. https://app.cochat.ai/papers/10.1007/s00134-020-06059-6
- The paper
- Leisman, D. E., Deutschman, C. S., & Legrand, M. (2020). Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Medicine. https://doi.org/10.1007/s00134-020-06059-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.